lobbying_activities: 2433404

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2433404	718772aa-eecf-4d8c-88bf-cd2fa3f455aa	Q1	WILLIAMS AND JENSEN, PLLC	41454	MERCK & CO INC	2020	first_quarter	MMM	Payment policies for Part B prescription drugs; Rebates and co-pays for Medicare Part D drug benefits; Possible revisions in structure and operation of Medicare and Medicaid drug policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,White House Office	80000		0	0	2020-04-17T16:20:51.220000-04:00